Back to top
more

Danaher (DHR)

(Delayed Data from NYSE)

$190.46 USD

190.46
2,791,958

-2.83 (-1.46%)

Updated Sep 22, 2025 04:00 PM ET

After-Market: $190.46 0.00 (0.00%) 6:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 245)

Industry: Medical Services

Zacks News

Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.

Zacks Equity Research

Can Danaher (DHR) Keep Earnings Beat Streak Alive in Q3?

Danaher's (DHR) third-quarter earnings are expected to reflect the impact of Danaher Business System, acquired assets, solid product offerings and innovation. Forex and cost woes remain.

Zacks Equity Research

Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Reasons Why Investors Should Avoid 3M (MMM) Stock for Now

3M (MMM) suffers from weakness in organic sales, high costs of sales, forex woes and high debts. Fall in cash flow generation is also concerning.

Zacks Equity Research

Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Honeywell Unveils New Hearing Solution for Worker Safety

Honeywell's (HON) VeriShield Smart Hearing Solution will assist companies in improving their hearing conservation programs with a personalized approach to worker protection.

Zacks Equity Research

GE to Offer Onshore Wind Turbine Solution to EDF Renewables

General Electric's (GE) onshore wind turbine solution - Cypress platform - is likely to make EDF Renewables' Ventos da Bahia wind farm more efficient in producing renewable energy in Brazil.

Zacks Equity Research

Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Honeywell's (HON) Board Approves 10% Hike in Dividend Rate

Honeywell's (HON) latest hike marks its 10th double digit increment in dividend rate since 2010. Such shareholder-friendly policies of the company reflect a strong liquidity position.

Zacks Equity Research

Honeywell & KE2 Therm to Cut Energy Costs for Retail Grocers

Honeywell's (HON) partnership with KE2 Therm will help retail grocers to reduce energy costs and wastage apart from meeting regulatory instructions.

Zacks Equity Research

Danaher (DHR) Plans to Redeem $875M Worth of Senior Notes

Danaher (DHR) intends to redeem $875 million worth of senior notes. Funds received from Envista will be used for note redemption.

Zacks Equity Research

Danaher's (DHR) Subsidiary Envista Closes IPO, Shares Up

Danaher's (DHR) Envista closes its initial public offering and pays the proceeds to Danaher as part payment for its assets.

Zacks Equity Research

4 Stocks to Focus on Global Biotechnology Reagents Market

Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.

Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

Zacks Equity Research

Danaher's Subsidiary Envista Prices IPO, to Trade as NVST

Danaher's (DHR) subsidiary, Envista, goes public with an initial offering of roughly 26.8 million shares.

Mark Vickery headshot

Top Analyst Reports for AbbVie, Union Pacific & CSX

Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and CSX (CSX).

Zacks Equity Research

3M Launches 3M M*Modal CDI Engage One for Healthcare Market

3M's (MMM) 3M M*Modal CDI Engage One offers real-time clinical insight to clinical documentation improvement specialists, clinicians and coding teams.

Zacks Equity Research

Honeywell (HON) Commissions Technology for Zhejiang Satellite

Zhejiang Satellite uses Honeywell's (HON) C3 Oleflex technology for the production of polymer-grade propylene at its facility in China.

Zacks Equity Research

General Electric to Get Roughly $3B From Stake Sale in BHGE

General Electric's (GE) offering of Baker Hughes' shares to the public and Baker Hughes' decision to buy back own shares will likely raise roughly $3 billion. Funds will help in reducing debts.

Payal Jalan headshot

Diversified Operations Industry Near-Term Prospects Bright

Technological advancements, favorable conditions in end markets like aerospace and defense, restructuring efforts and pro-growth policies of the government are making conglomerates a favorable investment destination.

Zacks Equity Research

UTX or DHR: Which Is the Better Value Stock Right Now?

UTX vs. DHR: Which Stock Is the Better Value Option?

Zacks Equity Research

General Electric to Lose Controlling Stake in Baker Hughes

General Electric's (GE) offering of Baker Hughes' shares to the public and Baker Hughes' decision to buy back own shares comply with the restructuring plans announced in June 2018.

Zacks Equity Research

Danaher (DHR) Upgraded to Buy: Here's What You Should Know

Danaher (DHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Danaher's Senior Notes Offerings to Fund BioPharma Buyout

Danaher's (DHR) subsidiary prices euro 6.25 billion worth of senior notes offerings. The net proceeds will be used for paying for the pending acquisition of General Electric's BioPharma business.

Zacks Equity Research

Simple Market Timing Strategies That Work - September 02, 2019

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?